Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|November 4, 2025
6 Endocrinology Headlines You Missed in October 2025
Author(s)Ryan Livingston
Fact checked by: Tim Smith
Stay up to date with the groundbreaking FDA decisions, critical trial updates, and more news from the last month.
Advertisement
Advertisement
Endocrinology has been on an upward track for most of 2025, and October has continued this trend. With crucial approvals from the
Related to this article
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Advertisement
Advertisement